Novoste 40 mm Seed Train Addresses Clinical Concern Over "Edge" Effect
This article was originally published in The Gray Sheet
Executive Summary
Novoste plans to introduce into ongoing European and U.S. clinical trials this quarter a longer seed train for the Beta-Cath radiotherapy catheter system, which is intended to prevent possible restenosis at the edge of the treatment zone of a coronary vessel.
You may also be interested in...
Novoste Narrows Focus For Primary Indication In Light Of Beta-Cath Trial
Novoste Corp. is considering further evaluation of its Beta-Cath radiation system using a longer source train and a smaller diameter catheter in conjunction with initial angioplasty treatment.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.